Cargando…
The Interdisciplinary Stem Cell Institute’s Use of Food and Drug Administration-Expanded Access Guidelines to Provide Experimental Cell Therapy to Patients With Rare Serious Diseases
The U.S. Food and Drug Administration (FDA) provides guidance for expanded access to experimental therapies, which in turn plays an important role in the Twenty-first Century Cures Act mandate to advance cell-based therapy. In cases of incurable diseases where there is a lack of alternative treatmen...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217825/ https://www.ncbi.nlm.nih.gov/pubmed/34169074 http://dx.doi.org/10.3389/fcell.2021.675738 |
_version_ | 1783710670541291520 |
---|---|
author | Khan, Aisha Bellio, Michael A. Schulman, Ivonne H. Levi, Allan D. Longsomboon, Bangon Brooks, Adriana Valasaki, Krystalenia DiFede, Darcy L. Pujol, Marietsy V. Yavagal, Dileep R. Bates, Karen E. Si, Ming-Sing Kaushal, Sunjay Green, Barth A. Anderson, Kimberly D. Guest, James D. Burks, Stephen Shelby Silvera, Risset Santamaria, Andrea J. Lalwani, Anil Dietrich, W. Dalton Hare, Joshua M. |
author_facet | Khan, Aisha Bellio, Michael A. Schulman, Ivonne H. Levi, Allan D. Longsomboon, Bangon Brooks, Adriana Valasaki, Krystalenia DiFede, Darcy L. Pujol, Marietsy V. Yavagal, Dileep R. Bates, Karen E. Si, Ming-Sing Kaushal, Sunjay Green, Barth A. Anderson, Kimberly D. Guest, James D. Burks, Stephen Shelby Silvera, Risset Santamaria, Andrea J. Lalwani, Anil Dietrich, W. Dalton Hare, Joshua M. |
author_sort | Khan, Aisha |
collection | PubMed |
description | The U.S. Food and Drug Administration (FDA) provides guidance for expanded access to experimental therapies, which in turn plays an important role in the Twenty-first Century Cures Act mandate to advance cell-based therapy. In cases of incurable diseases where there is a lack of alternative treatment options, many patients seek access to cell-based therapies for the possibility of treatment responses demonstrated in clinical trials. Here, we describe the use of the FDA’s expanded access to investigational new drug (IND) to address rare and emergency conditions that include stiff-person syndrome, spinal cord injury, traumatic brain stem injury, complex congenital heart disease, ischemic stroke, and peripheral nerve injury. We have administered both allogeneic bone marrow-derived mesenchymal stem cell (MSC) and autologous Schwann cell (SC) therapy to patients upon emergency request using Single Patient Expanded Access (SPEA) INDs approved by the FDA. In this report, we present our experience with 10 completed SPEA protocols. |
format | Online Article Text |
id | pubmed-8217825 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82178252021-06-23 The Interdisciplinary Stem Cell Institute’s Use of Food and Drug Administration-Expanded Access Guidelines to Provide Experimental Cell Therapy to Patients With Rare Serious Diseases Khan, Aisha Bellio, Michael A. Schulman, Ivonne H. Levi, Allan D. Longsomboon, Bangon Brooks, Adriana Valasaki, Krystalenia DiFede, Darcy L. Pujol, Marietsy V. Yavagal, Dileep R. Bates, Karen E. Si, Ming-Sing Kaushal, Sunjay Green, Barth A. Anderson, Kimberly D. Guest, James D. Burks, Stephen Shelby Silvera, Risset Santamaria, Andrea J. Lalwani, Anil Dietrich, W. Dalton Hare, Joshua M. Front Cell Dev Biol Cell and Developmental Biology The U.S. Food and Drug Administration (FDA) provides guidance for expanded access to experimental therapies, which in turn plays an important role in the Twenty-first Century Cures Act mandate to advance cell-based therapy. In cases of incurable diseases where there is a lack of alternative treatment options, many patients seek access to cell-based therapies for the possibility of treatment responses demonstrated in clinical trials. Here, we describe the use of the FDA’s expanded access to investigational new drug (IND) to address rare and emergency conditions that include stiff-person syndrome, spinal cord injury, traumatic brain stem injury, complex congenital heart disease, ischemic stroke, and peripheral nerve injury. We have administered both allogeneic bone marrow-derived mesenchymal stem cell (MSC) and autologous Schwann cell (SC) therapy to patients upon emergency request using Single Patient Expanded Access (SPEA) INDs approved by the FDA. In this report, we present our experience with 10 completed SPEA protocols. Frontiers Media S.A. 2021-06-08 /pmc/articles/PMC8217825/ /pubmed/34169074 http://dx.doi.org/10.3389/fcell.2021.675738 Text en Copyright © 2021 Khan, Bellio, Schulman, Levi, Longsomboon, Brooks, Valasaki, DiFede, Pujol, Yavagal, Bates, Si, Kaushal, Green, Anderson, Guest, Burks, Silvera, Santamaria, Lalwani, Dietrich and Hare. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Khan, Aisha Bellio, Michael A. Schulman, Ivonne H. Levi, Allan D. Longsomboon, Bangon Brooks, Adriana Valasaki, Krystalenia DiFede, Darcy L. Pujol, Marietsy V. Yavagal, Dileep R. Bates, Karen E. Si, Ming-Sing Kaushal, Sunjay Green, Barth A. Anderson, Kimberly D. Guest, James D. Burks, Stephen Shelby Silvera, Risset Santamaria, Andrea J. Lalwani, Anil Dietrich, W. Dalton Hare, Joshua M. The Interdisciplinary Stem Cell Institute’s Use of Food and Drug Administration-Expanded Access Guidelines to Provide Experimental Cell Therapy to Patients With Rare Serious Diseases |
title | The Interdisciplinary Stem Cell Institute’s Use of Food and Drug Administration-Expanded Access Guidelines to Provide Experimental Cell Therapy to Patients With Rare Serious Diseases |
title_full | The Interdisciplinary Stem Cell Institute’s Use of Food and Drug Administration-Expanded Access Guidelines to Provide Experimental Cell Therapy to Patients With Rare Serious Diseases |
title_fullStr | The Interdisciplinary Stem Cell Institute’s Use of Food and Drug Administration-Expanded Access Guidelines to Provide Experimental Cell Therapy to Patients With Rare Serious Diseases |
title_full_unstemmed | The Interdisciplinary Stem Cell Institute’s Use of Food and Drug Administration-Expanded Access Guidelines to Provide Experimental Cell Therapy to Patients With Rare Serious Diseases |
title_short | The Interdisciplinary Stem Cell Institute’s Use of Food and Drug Administration-Expanded Access Guidelines to Provide Experimental Cell Therapy to Patients With Rare Serious Diseases |
title_sort | interdisciplinary stem cell institute’s use of food and drug administration-expanded access guidelines to provide experimental cell therapy to patients with rare serious diseases |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217825/ https://www.ncbi.nlm.nih.gov/pubmed/34169074 http://dx.doi.org/10.3389/fcell.2021.675738 |
work_keys_str_mv | AT khanaisha theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT belliomichaela theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT schulmanivonneh theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT levialland theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT longsomboonbangon theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT brooksadriana theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT valasakikrystalenia theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT difededarcyl theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT pujolmarietsyv theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT yavagaldileepr theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT bateskarene theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT simingsing theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT kaushalsunjay theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT greenbartha theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT andersonkimberlyd theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT guestjamesd theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT burksstephenshelby theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT silverarisset theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT santamariaandreaj theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT lalwanianil theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT dietrichwdalton theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT harejoshuam theinterdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT khanaisha interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT belliomichaela interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT schulmanivonneh interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT levialland interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT longsomboonbangon interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT brooksadriana interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT valasakikrystalenia interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT difededarcyl interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT pujolmarietsyv interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT yavagaldileepr interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT bateskarene interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT simingsing interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT kaushalsunjay interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT greenbartha interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT andersonkimberlyd interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT guestjamesd interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT burksstephenshelby interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT silverarisset interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT santamariaandreaj interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT lalwanianil interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT dietrichwdalton interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases AT harejoshuam interdisciplinarystemcellinstitutesuseoffoodanddrugadministrationexpandedaccessguidelinestoprovideexperimentalcelltherapytopatientswithrareseriousdiseases |